Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology ...

The event, the press release and the slides will also be available on the events section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be ...

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadershipWill build ...

Evommune has aced its first major test as a public company, reporting phase 2a eczema data that caused its share price to jump 75% in premarket trading. The biotech, which went public late last year, ...

Chronic and highly burdensome, atopic dermatitis affects an estimated 223 million people worldwide, with onset commonly occurring in infancy and childhood. Rising awareness among parents, coupled with ...

Nektar Therapeutics (NASDAQ:NKTR) stock rose 3% Tuesday morning after the company reported positive maintenance data from its REZOLVE-AD study for rezpegaldesleukin in patients with moderate-to-severe ...

Atopic dermatitis is associated with increased asthma and rhinitis worldwide, according to new global estimates. Learn more.

Nektar Therapeutics (NKTR) stock jumps on positive mid-stage trial data for its experimental drug targeting atopic dermatitis. Read more here.

Shares of Nektar Therapeutics (NASDAQ:NKTR) moved higher on Tuesday after the company released encouraging long-term maintenance results from its REZOLVE-AD trial of rezpegaldesleukin in patients with ...

In spite of its commonality, there are still plenty of unknowns around atopic dermatitis, including the actual cause of the skin condition. Perhaps that’s why there are so many myths surrounding it.

Evommune Inc. (EVMN) shares nearly doubled in value in Tuesday’s pre-market trade after the company reported positive results ...